Resource Center

Application Notes

See how AIQ Solutions is able to assist in understanding treatment in different applications
Early identification of both the benefits and the risks associated with immunotherapy are essential for the efficient development of effective therapies and will enable investigators to differentiate between patients who are likely to have an optimal vs. a sub-optimal response to therapy. This can impact the overall clinical outcome and reduce the number of severe or life-threatening adverse events, which are critical for guiding therapeutic management in the clinical setting.
See the document
By assessing patient treatment efficacy and toxicity risk earlier in theranostic therapy, investigators will be able to differentiate those patients who are likely to have an optimal vs. sub-optimal response. This information can impact the overall clinical outcome and reduce the number of severe or life-threatening adverse events, resulting in more efficient drug discovery timelines.
See the document
Resource Center

Learn more about AIQ Solutions TEchnology

Discover the publications and clinical research supporting AIQ Solutions technology platform
Explore publications
View posters that AIQ has presented or contributed to at different seminars and conferences
Review our posters
AIQ has multiple white papers which highlight our unique technology, heterogeneity, and other subjects
See white papers
See how AIQ Solutions is able to assist in understanding treatment in different applications
Review notes
See how AIQ Solutions is able to assist in understanding treatment in different applications
Review reports
Get insights from our team and keep up-to-date on interesting topics relating to AIQ technology
Read the blogs
Learn more about treatment response challenges facing clinical studies and patient management
Explore our videos
Learn how TRAQinform IQ™ technology has become an essential component of clinical studies.
See our webinars
Review policy documents showing how AIQ is complying with applicable regulations.
Review policies